Gender (male/female)
|
112/20
|
21.7/15.8
|
1.095 (0.625–1.917)
|
0.752
| | | | |
Age (< 60/≥60 years)
|
89/43
|
21.0/21.7
|
1.109 (0.720–1.708)
|
0.640
| | | | |
Etiology (HBV/other than HBV)
|
109/23
|
21.0/26.3
|
1.154 (0.688–1.934)
|
0.587
| | | | |
PLT (< 150/≥150 × 10E9/L)
|
74/58
|
21.7/21.4
|
0.970 (0.647–1.457)
|
0.885
| | | | |
Albumin (< 35/≥35 g/L)
|
20/112
|
14.3/23.4
|
1.627 (0.959–2.763)
|
0.071
| | | | |
Bilirubin (≥17/< 17 μmol/L)
|
51/81
|
15.9/27.1
|
1.573 (1.045–2.368)
|
0.030
|
1.397 (0.915–2.132)
|
0.121
|
1.371 (0.878–2.139)
|
0.165
|
AST (≥40/< 40 U/L)
|
69/63
|
14.8/32.7
|
2.008 (1.329–3.034)
|
0.001
|
1.859 (1.194–2.894)
|
0.006
|
1.854 (1.193–2.883)
|
0.006
|
ALT (≥40/< 40 U/L)
|
56/76
|
17.1/21.7
|
0.943 (0.624–1.427)
|
0.783
| | | | |
AFP (≥200/< 200 ng/ml)
|
67/65
|
15.7/28.7
|
1.533 (1.017–2.310)
|
0.041
|
1.364 (0.869–2.142)
|
0.178
|
1.379 (0.884–2.152)
|
0.157
|
Ascites (with/without)
|
15/117
|
12.6/21.9
|
1.975 (1.093–3.569)
|
0.024
|
1.136 (0.470–2.764)
|
0.777
|
1.149 (0.477–2.769)
|
0.757
|
Child-Pugh score (5/6/≥7)
|
104/20/8
|
25.1/17.1/12.5
|
1.606 (1.149–2.244)
|
0.006
|
1.895 (1.150–3.123)
|
0.012
|
1.907 (1.160–3.137)
|
0.011
|
Tumor size (≥7/< 7 cm)
|
71/61
|
16.5/26.3
|
1.457 (0.966–2.199)
|
0.073
| | | | |
No. of HCC nodules (≥2/1)
|
63/69
|
14.8/27.1
|
1.806 (1.200–2.718)
|
0.005
|
1.753 (1.134–2.709)
|
0.012
|
1.764 (1.138–2.733)
|
0.011
|
Sorafenib usage (after/before TACE)
|
43/89
|
22.9/21.0
|
0.932 (0.608–1.430)
|
0.747
| | | | |
Vascularity (hypovascular/hypervascular)
|
44/88
|
15.0/25.1
|
2.003 (1.300–3.085)
|
0.002
|
2.103 (1.355–3.266)
|
0.001
| | |
HFSR (non-responder/responder)
|
60/72
|
15.0/25.1
|
1.801 (1.201–2.700)
|
0.004
|
1.957 (1.281–2.991)
|
0.002
| | |
Stratification
|
Group A
|
52
|
29.1
|
1
| | | |
1
| |
Group BC
|
56
|
16.5
|
1.729 (1.085–2.758)
|
0.021
| | |
1.910 (1.167–3.127)
|
0.010
|
Group D
|
24
|
11.9
|
3.166 (1.802–5.563)
|
< 0.001
| | |
4.154 (2.311–7.465)
|
< 0.001
|